Galuba V, Cordes J, Feyerabend S, Riesbeck M, Meisenzahl-Lechner E, Correll CU, Kluge M, Neff A, Zink M, Langguth B, Reske D, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Schmidt-Kraepelin C, COMBINE Study Group . Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study. Schizophr Res. 2024 270:383-391. Epub 2024 Jul 9.
Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism. Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
Hart XM, Gründer G, Ansermot N, Conca A, Corruble E, Crettol S, Cumming P, Hefner G, Frajerman A, Howes O, Jukic M, Kim E, Kim S, Manisalco I, Moriguchi S, Müller DJ, Nakajima S, Osugo M, Paulzen M, Ruhe HG, Scherf-Clavel M, Schoretsanitis G, Serretti A, Spina E, Spigset O, Steimer W, Süzen HS, Uchida H, Unterecker S, Vandenberghe F, Verstuyft C, Zernig G, Hiemke C, Eap CB. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics. World J Biol Psychiatry. 2024 25(9):451-536. Epub 2024 Jun 24.
Hart XM, Spangemacher M, Defert J, Uchida H, Gründer G. Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants. Ther Drug Monit. 2024 46(2):155-169.
Hart XM, Spangemacher M, Uchida H, Gründer G. Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. Ther Drug Monit. 2024 46(1):16-32. Epub 2023 Nov 27.
Lense XM, Hiemke C, Funk CSM, Havemann-Reinecke U, Hefner G, Menke A, Mössner R, Riemer TG, Scherf-Clavel M, Schoretsanitis G, Gründer G, Hart X. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis. Psychopharmacology (Berl). 2024 241(2):275-289. Epub 2023 Oct 19.
Pedraz-Petrozzi B, Spangemacher M, Deicher A, Drews L, Defert J, Silva-Colmenero AY, Wein P, Riedinger E, Gründer G, Gilles M, Sartorius A, Reinwald JR. Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study. Front Psychiatry. 2024 15:1415505.
Spangemacher M, Hart X, Saalfrank E, Gründer G, Reinwald J, Sartorius A. Elevation of Alpha-1 Acid Glycoprotein During Acute Infection Increases Clozapine Levels Without Signs of Intoxication. J Clin Psychopharmacol. 2024 44(1):60-63.
Spangemacher M, Mertens L, Färber LV, Jungaberle A, Jungaberle H, Gründer G. Psilocybin as a Disease-Modifying Drug—a Salutogenic Approach in Psychiatry. Dtsch Arztebl Int. 2024 121(26):868-874. Epub 2024 Dec 27.
Wolff M, Evens R, Mertens LJ, Schmidt C, Beck J, Rutrecht H, Cherniak AD, Gründer G, Jungaberle H. Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ). J Psychopharmacol. 2024 38(5):432-457. Epub 2024 May 14.
Wong DF, Chand GB, Caito N, Eramo A, Grattan VT, Hixon MS, Nicol G, Lessie E, Prensky Z, Kuwabara H, Tian L, Valenta I, Schindler TH, Gründer G, Vaino AR. PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement. Neuropsychopharmacology. 2024 50(2):372-377. Epub 2024 Oct 16.